APLP2 and early-onset autosomal dominant Alzheimer disease: In research to develop improved treatments for Alzheimer’s disease, there has been considerable investigation of the cleavage of APP and APLP2, and inhibitors of β-secretases have been developed that block the cleavage of these proteins (1,54–56).